RPG Life Sciences Q1 Results: With a 22% increase in Q1 earnings, RPG Life Sciences achieves a 52-week high

On July 31, RPG Life Sciences' shares reached a 52-week high after the company's net profit for the June quarter increased by 22% over the same period last year to Rs 22 crore.

The revenue from operations for the first quarter of FY24 at RPG Life Sciences increased by 15% YoY to Rs 148 crore from Rs 129 crore reported in the first quarter of FY23.

EBITDA (Earnings-before-interest-taxes-depreciation and amortization) for the first quarter of FY24 was Rs 34 crore, up 17% year over year from Rs 29.1 crore recorded in the first quarter of FY23. The EBITDA margins slightly increased by 50 basis points to 23% in the quarter under review.

Pharmaceutical product manufacture and marketing are the main businesses of RPG Life Sciences. The business offers a variety of formulations and active pharmaceutical ingredients (APIs) and works in a number of therapeutic areas. Its activities include pharmaceutical product development, production, and distribution. RPG Life Sciences runs its business from two manufacturing sites in Gujarat and one API facility in Navi Mumbai.

Source: Media Reports